UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy

Journal of the European Academy of Dermatology and Venereology, 2005-01, Vol.19 (1), p.21-29

2005

Volltextzugriff (PDF)

Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study

British journal of dermatology (1951), 2019-05, Vol.180 (5), p.1050-1057

2019

Volltextzugriff (PDF)

90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse

Journal of investigative dermatology, 2023-11, Vol.143 (11), p.S347

2023

Volltextzugriff (PDF)

The use of tetracyclines for the treatment of sarcoidosis

Archives of dermatology (1960), 2001-01, Vol.137 (1), p.69

2001

Volltextzugriff (PDF)

Tolérance rénale de la ciclosporine au long cours dans le psoriasis

Annales de dermatologie et de vénéréologie, 2000, Vol.127 (2), p.180-183

2000

Volltextzugriff (PDF)

FS03.5Evaluation of the irritancy potential of adapalene and tretinoin in volunteers of different ethnic origins

Contact dermatitis, 2004-03, Vol.50 (3), p.135-135

2004

Volltextzugriff (PDF)

FS03.5 Evaluation of the irritancy potential of adapalene and tretinoin in volunteers of different ethnic origins

Contact dermatitis, 2004-03, Vol.50 (3), p.135-135

2004

Volltextzugriff (PDF)

Renal function during long-term cyclosporin treatment of psoriasis

Annales de dermatologie et de vénéréologie, 2000-02, Vol.127 (2), p.180

2000

Volltextzugriff (PDF)

Omalizumab – an effective and safe treatment of therapy‐resistant chronic spontaneous urticaria

Allergy (Copenhagen), 2011-02, Vol.66 (2), p.303-305

2011

Volltextzugriff (PDF)

51223 A novel human disease model of alopecia areata to evaluate benefit of the DHODH inhibitor farudodstat

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB9-AB9

2024

Volltextzugriff (PDF)

Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria

Annals of allergy, asthma, & immunology, 2010-03, Vol.104 (3), p.253-258

2010

Volltextzugriff (PDF)

53652 Efficacy and safety of eblasakimab in adults with severe atopic dermatitis: a posthoc analysis of the Phase 2b TREK-AD trial

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB194-AB194

2024

Volltextzugriff (PDF)

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

Journal of the American Academy of Dermatology, 2024-03, Vol.90 (3), p.504-511

2024

Volltextzugriff (PDF)

Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials

Journal of drugs in dermatology, 2018-09, Vol.17 (9), p.987

2018

Volltextzugriff (PDF)

Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials

Journal of drugs in dermatology, 2016-08, Vol.15 (8), p.962

2016

Volltextzugriff (PDF)

Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials

Journal of drugs in dermatology, 2016-05, Vol.15 (5), p.553

2016

Volltextzugriff (PDF)

Safety and Pharmacokinetics of Once-Daily Dapsone Gel, 7.5% in Patients With Moderate Acne Vulgaris

Journal of drugs in dermatology, 2016-10, Vol.15 (10), p.1250

2016

Volltextzugriff (PDF)

A new oral liquid formula including high dose prednisolone

Clinical and translational allergy, 2011-08, Vol.1 (S1), p.P107-n/a, Article P107

2011

Volltextzugriff (PDF)

Treatment Response With Once-Daily Topical Dapsone Gel, 7.5% for Acne Vulgaris: Subgroup Analysis of Pooled Data from Two Randomized, Double-Blind Stu

Journal of drugs in dermatology, 2017-06, Vol.16 (6), p.591

2017

Volltextzugriff (PDF)

Efficacy, Safety, and Dermal Tolerability of Dapsone Gel, 7.5% in Patients with Moderate Acne Vulgaris: A Pooled Analysis of Two Phase 3 Trials

The Journal of clinical and aesthetic dermatology, 2016-10, Vol.9 (10), p.18-27

2016

Volltextzugriff (PDF)

Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials

Skin (Milwood, N.Y.), 2020-09, Vol.4 (5), p.s52

2020

Volltextzugriff (PDF)

Intravenous Immunoglobulin as a Third-Line Therapy in Chronic Spontaneous Urticaria

Annals of allergy, asthma, & immunology, 2010-09, Vol.105 (3), p.245-246

2010

Volltextzugriff (PDF)

Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria: Allergy Net

Allergy (Copenhagen), 2011-02, Vol.66 (2), p.303-305

2011

Volltextzugriff (PDF)

Adapalene gel 0.1% is better tolerated than tretinoin gel 0.025% among healthy volunteers of various ethnic origins

The Journal of dermatological treatment, 2009, Vol.20 (5), p.282-288

2009

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(25)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy

Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study

90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse

The use of tetracyclines for the treatment of sarcoidosis

Tolérance rénale de la ciclosporine au long cours dans le psoriasis

FS03.5Evaluation of the irritancy potential of adapalene and tretinoin in volunteers of different ethnic origins

FS03.5 Evaluation of the irritancy potential of adapalene and tretinoin in volunteers of different ethnic origins

Renal function during long-term cyclosporin treatment of psoriasis

Omalizumab – an effective and safe treatment of therapy‐resistant chronic spontaneous urticaria

51223 A novel human disease model of alopecia areata to evaluate benefit of the DHODH inhibitor farudodstat

Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria

53652 Efficacy and safety of eblasakimab in adults with severe atopic dermatitis: a posthoc analysis of the Phase 2b TREK-AD trial

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials

Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials

Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials

Safety and Pharmacokinetics of Once-Daily Dapsone Gel, 7.5% in Patients With Moderate Acne Vulgaris

A new oral liquid formula including high dose prednisolone

Treatment Response With Once-Daily Topical Dapsone Gel, 7.5% for Acne Vulgaris: Subgroup Analysis of Pooled Data from Two Randomized, Double-Blind Stu

Efficacy, Safety, and Dermal Tolerability of Dapsone Gel, 7.5% in Patients with Moderate Acne Vulgaris: A Pooled Analysis of Two Phase 3 Trials

Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials

Intravenous Immunoglobulin as a Third-Line Therapy in Chronic Spontaneous Urticaria

Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria: Allergy Net

Haut und Schleimhäute

Adapalene gel 0.1% is better tolerated than tretinoin gel 0.025% among healthy volunteers of various ethnic origins

Suchergebnisse filtern